CRISPR Therapeutics

This week, our CEO & Chairman Samarth Kulkarni, PhD, with members of our team and Board of Directors, rang the Opening Bell at the Nasdaq MarketSite Studio in Times Square to celebrate our recent milestones and growth. We’re proud to ring in our success as a company and the impact we can have on people living with serious diseases. Watch the Opening Bell ceremony here: https://bit.ly/4dL3BfE   Photography courtesy of Nasdaq, Inc.

May is #NationalCancerResearchMonth. The American Association for Cancer Research initiated and supports National Cancer Research Month, which aims to acknowledge the importance of innovative research to aid those who are impacted by cancers. CRISPR Therapeutics is proud to work toward our mission of transforming the lives of people living with serious diseases such as cancers. Learn more about #NationalCancerResearchMonth here: https://bit.ly/4aqqyma #NCRM24

The Precision Health Alliance, a new consortium co-founded by Duke Clinical Research Institute, CRISPR Therapeutics, Beam Therapeutics, Intellia Therapeutics, Inc., and Verve Therapeutics, launched this week and will focus on innovation in precision medicine and gene editing. Learn more here: phgea.org.

We're thrilled to share that CRISPR Therapeutics will ring the Opening Bell this morning at the Nasdaq MarketSite Studio in Times Square.     We’re excited to commemorate the historic first-ever approval of a CRISPR-based therapy and celebrate innovation as we continue to expand and advance our programs for rare and common diseases.    Join us by tuning in for the livestream here starting at 9:15am ET: https://lnkd.in/eJz78vY  

This week, Samarth Kulkarni, PhD, CRISPR Therapeutics CEO & Chairman, spoke at the Milken Institute Global Conference about biomedical breakthroughs, how to accelerate innovation and scalability, and the future for in vivo gene editing. Watch the replay here: https://bit.ly/3UDr0Xm #MIGlobal

Today, we announced our first quarter earnings results. Read more about our recent highlights and outlook in our business update: https://bit.ly/4dtPpYb #CRSP #CRISPRTX 

Today, we announced new preclinical data presented at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) 2024 highlighting our approach to developing lipid nanoparticle (LNP) based delivery for in vivo ocular gene editing. Learn more here: https://bit.ly/3yejV8o #ASGCT2024 

In collaboration with Vertex Pharmaceuticals, we're pleased to share that we’ve published three new publications in The New England Journal of Medicine (NEJM) containing clinical data on the treatment for sickle cell disease and beta thalassemia. 

We’re looking forward to presenting an oral presentation highlighting our lipid nanoparticle (LNP) approach for ocular editing at the upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting on May 8, 2024. Learn more here: https://bit.ly/49NOBKv #ASGCT2024 

The CRISPR era is here – and we’re proud to be at the forefront. Thank you The Atlantic for inviting our CEO Dr. Samarth Kulkarni to the Atlantic Health Summit to discuss how CRISPR is pioneering a new era of medicine with potential applications for a range of serious diseases. #CRISPRTX #AtlanticHealth #Innovation